Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.
Front Immunol. 2020 Feb 28;11:379. doi: 10.3389/fimmu.2020.00379. eCollection 2020.
The bacterium (FP), which is found in human feces, has been reported to participate in catechin metabolism in the gut, but this bacterium's effects on immune function are unclear. We assessed the effect of oral administration of FP on the immune response in ovalbumin (OVA) -sensitized mice. We demonstrated that the FP treatment suppressed interleukin (IL)-4 in splenocytes and OVA-specific IgE production in serum from OVA-sensitized mice. Moreover, oral administration of FP augmented CD4CD25 T cells and CD103CD11c DCs. In animals of the FP group, the proportion of FP was increased in the mesenteric lymph nodes (MLNs), as was the proportion of Deferribacteres in the cecum. Oral administration of FP may inhibit the Th2 immune response by incorporation into the MLNs and/or by inducing changes in the gut microbiota. Thus, FP may be useful in alleviating antigen-induced Th2 immune responses.
该细菌（FP）存在于人类粪便中，据报道其参与肠道内儿茶素的代谢，但该细菌对免疫功能的影响尚不清楚。我们评估了口服 FP 对卵清蛋白（OVA）致敏小鼠免疫应答的影响。结果表明，FP 处理抑制了致敏小鼠脾细胞中的白细胞介素（IL）-4 和血清中 OVA 特异性 IgE 的产生。此外，口服 FP 可增加 CD4+CD25+T 细胞和 CD103+CD11c+DCs。在 FP 组动物中，肠系膜淋巴结（MLNs）中 FP 的比例增加，盲肠中 Deferribacteres 的比例也增加。口服 FP 可能通过整合到 MLNs 中或通过诱导肠道微生物群的变化来抑制 Th2 免疫应答。因此，FP 可能有助于缓解抗原诱导的 Th2 免疫应答。
